• preview-full-smalXcovery_PMS blue
  • For Medical Professionals
    • Ensartinib (ALK Inhibitor X-396)
    • Clinical Trials
    • Patient Resources
    • Investigational Agents
    • Expanded Acccess Policy
    • Close
  • Living with ALK+
    • What is ALK+ Lung Cancer
    • What is Ensartinib
    • Expanded Access Policy
    • Your Resources
    • Close
  • Our Studies
    • eXalt3
    • eXalt2
    • vorolanib
    • About Clinical Trials
    • Close
  • Our Science
  • About Us
    • Our News & Events
    • Our Vision & Culture
    • Our Leadership
    • Partnerships
    • Join Our Team
    • Contact Us
    • Close
Join a study for ALK+ Lung Cancer
February 7, 2018

Ensartinib in Melanoma Press Release. Please click on the link below for details. You can find more information on this and other Ensartinib trials on the clinicaltrials.gov website.

News 0

Xcovery Announces Initiation of Phase 2 Clinical Trial for Ensartinib in Melanoma Patients with ALK Alternations

Ensartinib Effective, Well-Tolerated in Patients With ALK+, TKI-Naive NSCLC European Lung Cancer Congress (ELCC) in Geneva, Switzerland – April 11-14, 2018

Related Posts

News

Ensartinib Effective, Well-Tolerated in Patients With ALK+, TKI-Naive NSCLC

News

IASLC 18th World Conference on Lung Cancer, Yokohama, Japan

News

IASLC 18th World Conference on Lung Cancer, Yokohama, Japan

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

FOR MORE INFORMATION

EMAIL US

OR

CALL 561-835-9356

©2017 XCOVERY ALL RIGHTS RESERVED.
  • Contact Us
  • Privacy
YOU ARE LEAVING THE XCOVERY SITE.

XCOVERY IS NOT RESPONSIBLE FOR AND DOES NOT HAVE CONTROL

OR INFLUENCE OVER CONTENT,

ACCURACY OR VIEWS EXPRESSED ON EXTERNAL WEBSITES.

TO RETURN TO XCOVERY.COM (CLICK HERE)

TO LEAVE XCOVERY.COM (CLICK HERE)

YOU ARE LEAVING THE XCOVERY SITE.

XCOVERY IS NOT RESPONSIBLE FOR AND DOES NOT HAVE CONTROL

OR INFLUENCE OVER CONTENT,

ACCURACY OR VIEWS EXPRESSED ON EXTERNAL WEBSITES.

TO RETURN TO XCOVERY.COM (CLICK HERE)

TO LEAVE XCOVERY.COM (CLICK HERE)

YOU ARE LEAVING THE XCOVERY SITE.

XCOVERY IS NOT RESPONSIBLE FOR AND DOES NOT HAVE CONTROL

OR INFLUENCE OVER CONTENT,

ACCURACY OR VIEWS EXPRESSED ON EXTERNAL WEBSITES.

TO RETURN TO XCOVERY.COM (CLICK HERE)

TO LEAVE XCOVERY.COM (CLICK HERE)